Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 2.12765957447 | 1.41 | 1.452 | 1.38 | 55474 | 1.40412329 | CS |
| 4 | 0.02 | 1.40845070423 | 1.42 | 1.515 | 1.38 | 65747 | 1.43106057 | CS |
| 12 | 0.31 | 27.4336283186 | 1.13 | 1.68 | 1.07 | 231741 | 1.48839701 | CS |
| 26 | 0.18 | 14.2857142857 | 1.26 | 1.68 | 0.9612 | 169601 | 1.37924934 | CS |
| 52 | 0.4 | 38.4615384615 | 1.04 | 1.68 | 0.9612 | 159325 | 1.28102421 | CS |
| 156 | -58.53 | -97.5987993997 | 59.97 | 59.97 | 0.9612 | 94855 | 2.84595064 | CS |
| 260 | -58.53 | -97.5987993997 | 59.97 | 59.97 | 0.9612 | 56732 | 2.84595064 | CS |
suzuki1a
7分前
nwsun
14分前
jjjjjjjj
21分前
rich2
21分前
SamuiUmi
26分前
Winsmore
31分前
somberfox
46分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。